FDA Approves KEYTRUDA As Adjuvant Treatment Following Surgical Resection And Platinum-Based Chemotherapy For Patients With Stage IB (T2a ≥4 Centimeters), II, Or IIIA Non-Small Cell Lung Cancer (NSCLC)
FDA Approves KEYTRUDA As Adjuvant Treatment Following Surgical Resection And Platinum-Based Chemotherapy For Patients With Stage IB (T2a ≥4 Centimeters), II, Or IIIA Non-Small Cell Lung Cancer (NSCLC)
FDA 批准凱特魯達作為手術切除和鉑基化療後的輔助治療,用於 IB 期(T2A ≥4 厘米),II 或 IIIA 非小細胞肺癌(NSCLC)患者
FDA Approves KEYTRUDA As Adjuvant Treatment Following Surgical Resection And Platinum-Based Chemotherapy For Patients With Stage IB (T2a ≥4 Centimeters), II, Or IIIA Non-Small Cell Lung Cancer (NSCLC)
FDA批准KEYTRUDA作為手術切除和以鉑為基礎的化療後的輔助治療,用於IB期(T2â‰元4釐米)、II期或IIIA期非小細胞肺癌患者